LLY vs BSX
By Alex · Tickerpine
Eli Lilly and Company vs Boston Scientific Corporation, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BSX |
|---|---|---|
| Price | $1,273.46 | $45.69 |
| Market cap | $1.14T | $66.22B |
| P/E ratio | 42.7 | 18.5 |
| ROE | 102.29% | 15.34% |
| Profit margin | 33.53% | 17.50% |
| Revenue growth | 47.70% | 7.50% |
| Dividend yield | 0.54% | 0.00% |
| Beta | 0.45 | 0.57 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BSX in plain English
- LLY is the bigger company — about 17.2× the market cap of BSX.
- BSX is cheaper on earnings (P/E 18.5 vs 42.7).
- LLY earns a higher return on equity (102% vs 15%).
- LLY is growing revenue faster (48% vs 8%).
- LLY pays a dividend (0.54%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BSX return calculator
See what $1,000 in Boston Scientific Corporation would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.